By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CureVac GmbH 

Paul-Ehrlich-Str. 15

Tübingen    72076  Germany
Phone: 49-7071-92053-0 Fax: 49-7071-92053-11



Company News
CureVac Appoints Daniel Menichella As CEO Of CureVac Inc., The Company's U.S. Subsidiary 5/2/2017 8:53:20 AM
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017 5:45:05 AM
Study With CureVac's RNAdjuvant Technology Published In Cancer Immunology, Immunotherapy, Demonstrates Equal Responsiveness Of Blood Cells From Both Hepatocellular Carcinoma (HCC) Patients And Healthy Subjects To The RNA-Based Adjuvant 12/5/2016 6:57:53 AM
CureVac Secures An Additional $29.5 Million From Two New Investors 11/9/2016 12:54:16 PM
CureVac Receives Broad Patent For RNAntibody Technology 11/9/2016 11:56:18 AM
CureVac Appoints Pierre Kemula As Chief Financial Officer 10/11/2016 6:36:11 AM
CureVac Release: Study In Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode Of Action Of mRNA Vaccines 7/14/2016 8:52:56 AM
CureVac Appoints Leading Experts To Its Scientific Advisory Board 3/30/2016 7:42:20 AM
CureVac Strengthens Supervisory Board To Support Global Growth Opportunities And mRNA Product Expansion 3/21/2016 8:26:38 AM
CureVac Announces "MERAN" Has Been Approved By The WHO As Suffix For Mrna Drug Substances 2/18/2016 10:29:33 AM